Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Child-resistant packaging

This article was originally published in The Rose Sheet

Executive Summary

Topical OTC drugs are not included in Consumer Product Safety Commission's notice of proposed rulemaking requiring child-resistant packaging for Rx-to-OTC switch drug products published in the Federal Register Aug. 30. The rule would apply only to switched oral drug products, including certain antihistamine active ingredients. CPSC also is proposing to reverse a requirement that companies wait until FDA approves an OTC switch before applying for a CRP exemption. Comments are due Nov. 13
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS008383

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel